Contributions
Abstract: EP1735
Type: ePoster
Abstract Category: Therapy - disease modifying - 29 Risk management for disease modifying treatments
Background: Anti- JCV antibody index is the predicting factor of progressive multifocal leukoencephalopathy (PML) for multiple sclerosis (MS) patients treating with Natalizumab.
Objectives: To evaluate the prevalence of anti-JCV antibody positivity and high index among Iranian patients who are the candidate for Natalizumab to see its correlation with their demographic data.
Method: This cross-sectional study assessed all received anti-JCV Antibody test result of Iranian MS patients between Jan 2014 and Dec 2016. Demographic data and disease characteristics were also obtained. After data quality control, statistical analysis was done using logistic regression.
Results: Among 803 MS patients that were observed, prevalence of anti-JCV antibody positivity was 67.9% (mean of index=2.23; standard deviation (SD) =1.16) and 67.6 % of positive patients had index ≥ 1.5. Males were more anti-JCV antibody positive than females (81.7% and 64% respectively; significance sig. < 0.001, crude OR =2.51, CI: 1.65-3.81). Patients with 50 ≤ years old age (y.) comparing to patients with ≤18 y. had higher positivity prevalence (sig. =0.021; adjusted OR = 3.45, CI: 1.20-2.86). Patients who lived in cold regions had significantly more prevalence of positivity (Number of cases=403; sig. = 0.043 and crude OR = 1.86, CI: 1.02-3.39) and higher rate of index ≥ 1.5 (sig. = 0.017; crude OR=3.99, CI: 1.79-8.88). Disease onset age between 28 to 37 y. were more positive comparing to 18 to 27 y.
(N= 480; sig. =0.02; adjusted OR=1.85, CI: 1.09-3.14) but correlated reversely with index (sig. =0.01).
Conclusions: Age, male gender, onset age, cold area residency significantly influenced anti-JCV antibody positivity prevalence. Only age of onset and cold area residency related to the index. No significant difference observed between the previous type of disease modifying drugs, dosage and duration of treating with them and anti-JCV antibody positivity and its index.
Disclosure:
Founding source: this study was funded by Tehran University of medical sciences.
Conflict of interest: authors declare no conflict of interest.
Abstract: EP1735
Type: ePoster
Abstract Category: Therapy - disease modifying - 29 Risk management for disease modifying treatments
Background: Anti- JCV antibody index is the predicting factor of progressive multifocal leukoencephalopathy (PML) for multiple sclerosis (MS) patients treating with Natalizumab.
Objectives: To evaluate the prevalence of anti-JCV antibody positivity and high index among Iranian patients who are the candidate for Natalizumab to see its correlation with their demographic data.
Method: This cross-sectional study assessed all received anti-JCV Antibody test result of Iranian MS patients between Jan 2014 and Dec 2016. Demographic data and disease characteristics were also obtained. After data quality control, statistical analysis was done using logistic regression.
Results: Among 803 MS patients that were observed, prevalence of anti-JCV antibody positivity was 67.9% (mean of index=2.23; standard deviation (SD) =1.16) and 67.6 % of positive patients had index ≥ 1.5. Males were more anti-JCV antibody positive than females (81.7% and 64% respectively; significance sig. < 0.001, crude OR =2.51, CI: 1.65-3.81). Patients with 50 ≤ years old age (y.) comparing to patients with ≤18 y. had higher positivity prevalence (sig. =0.021; adjusted OR = 3.45, CI: 1.20-2.86). Patients who lived in cold regions had significantly more prevalence of positivity (Number of cases=403; sig. = 0.043 and crude OR = 1.86, CI: 1.02-3.39) and higher rate of index ≥ 1.5 (sig. = 0.017; crude OR=3.99, CI: 1.79-8.88). Disease onset age between 28 to 37 y. were more positive comparing to 18 to 27 y.
(N= 480; sig. =0.02; adjusted OR=1.85, CI: 1.09-3.14) but correlated reversely with index (sig. =0.01).
Conclusions: Age, male gender, onset age, cold area residency significantly influenced anti-JCV antibody positivity prevalence. Only age of onset and cold area residency related to the index. No significant difference observed between the previous type of disease modifying drugs, dosage and duration of treating with them and anti-JCV antibody positivity and its index.
Disclosure:
Founding source: this study was funded by Tehran University of medical sciences.
Conflict of interest: authors declare no conflict of interest.